Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer Following Failure of First-line Platinum-containing Chemotherapy: a Multicenter, Single-arm Prospective Phase II Clinical Study (STAMP Study)
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Catequentinib (Primary) ; Fuzuloparib (Primary)
- Indications Carcinoma; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms STAMP Study
- 14 Aug 2023 Trial design published in the BMC Cancer
- 24 Jun 2021 New trial record